메뉴 건너뛰기




Volumn 33, Issue 12, 2011, Pages 2029-2037

Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose, Two-Sequence, Crossover Study in Healthy Korean Male Volunteers

Author keywords

Enbrel; Healthy; Pharmacokinetics; Tumor necrosis factor antagonist; TuNEX

Indexed keywords

ETANERCEPT; GENERIC DRUG;

EID: 83455201580     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.022     Document Type: Article
Times cited : (33)

References (19)
  • 1
    • 47249153519 scopus 로고    scopus 로고
    • Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics
    • Feldmann M., Maini S.R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008, 223:7-19.
    • (2008) Immunol Rev , vol.223 , pp. 7-19
    • Feldmann, M.1    Maini, S.R.2
  • 2
    • 0035306510 scopus 로고    scopus 로고
    • Uncoupling of inflammatory and destructive mechanisms in arthritis
    • van den Berg W.B. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001, 30:7-16.
    • (2001) Semin Arthritis Rheum , vol.30 , pp. 7-16
    • van den Berg, W.B.1
  • 3
    • 3442875303 scopus 로고    scopus 로고
    • Pathogenesis of bone and cartilage destruction in rheumatoid arthritis
    • Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(Suppl 2):ii11-ii16.
    • (2003) Rheumatology (Oxford) , vol.42 , Issue.SUPPL. 2
    • Goldring, S.R.1
  • 4
    • 0023742630 scopus 로고
    • Tumour necrosis factor in synovial exudates
    • Di Giovine F.S., Nuki G., Duff G.W. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988, 47:768-772.
    • (1988) Ann Rheum Dis , vol.47 , pp. 768-772
    • Di Giovine, F.S.1    Nuki, G.2    Duff, G.W.3
  • 5
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group
    • Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
    • (1999) Lancet , vol.354 , pp. 1932-1939
    • Maini, R.1    St Clair, E.W.2    Breedveld, F.3
  • 6
    • 79251471130 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
    • Mewar D., Wilson A.G. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011, 162:785-791.
    • (2011) Br J Pharmacol , vol.162 , pp. 785-791
    • Mewar, D.1    Wilson, A.G.2
  • 7
    • 84855345966 scopus 로고    scopus 로고
    • PubMed.gov, US National Library of Medicine National Institutes of HealthUS National Library of Medicine National Institutes of Health, Accessed June 22, 2011
    • PubMed.gov, US National Library of Medicine National Institutes of HealthUS National Library of Medicine National Institutes of Health, Accessed June 22, 2011. http://www.ncbi.nlm.nih.gov/pubmed.
  • 8
    • 0010235710 scopus 로고    scopus 로고
    • This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999
    • Diagnostic Standards and Classification of Tuberculosis in Adults and Children
    • This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000, 161:1376-1395. Diagnostic Standards and Classification of Tuberculosis in Adults and Children.
    • (2000) Am J Respir Crit Care Med , vol.161 , pp. 1376-1395
  • 12
    • 0003484310 scopus 로고    scopus 로고
    • U.S. Food Drug Administration, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC
    • Guidance for Industry, Bioanalytical Method Validation 2001, U.S. Food Drug Administration, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC.
    • (2001) Guidance for Industry, Bioanalytical Method Validation
  • 13
    • 0025363405 scopus 로고
    • Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope
    • Lipsitz L.A., Mietus J., Moody G.B., Goldberger A.L. Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope. Circulation 1990, 81:1803-1810.
    • (1990) Circulation , vol.81 , pp. 1803-1810
    • Lipsitz, L.A.1    Mietus, J.2    Moody, G.B.3    Goldberger, A.L.4
  • 15
    • 0033975145 scopus 로고    scopus 로고
    • The pharmacokinetics of etanercept in healthy volunteers
    • Korth-Bradley J.M., Rubin A.S., Hanna R.K., et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000, 34:161-164.
    • (2000) Ann Pharmacother , vol.34 , pp. 161-164
    • Korth-Bradley, J.M.1    Rubin, A.S.2    Hanna, R.K.3
  • 16
    • 33644990468 scopus 로고    scopus 로고
    • The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects
    • Kawai S., Sekino H., Yamashita N., Tsuchiwata S., et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol 2006, 46:418-423.
    • (2006) J Clin Pharmacol , vol.46 , pp. 418-423
    • Kawai, S.1    Sekino, H.2    Yamashita, N.3    Tsuchiwata, S.4
  • 17
    • 1942508209 scopus 로고    scopus 로고
    • Absence of a pharmacokinetic interaction between etanercept and warfarin
    • Zhou H., Patat A., Parks V., et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004, 44:543-550.
    • (2004) J Clin Pharmacol , vol.44 , pp. 543-550
    • Zhou, H.1    Patat, A.2    Parks, V.3
  • 18
    • 17644386569 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
    • Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005, 45:490-497.
    • (2005) J Clin Pharmacol , vol.45 , pp. 490-497
    • Zhou, H.1
  • 19
    • 0037384060 scopus 로고    scopus 로고
    • Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
    • Lee H., Kimko H.C., Rogge M., et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003, 73:348-365.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 348-365
    • Lee, H.1    Kimko, H.C.2    Rogge, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.